Baseline PSA Screening and Long-Term Prostate Cancer Risk

​Baseline levels of prostate-specific antigen (PSA) at age 55 to 60 are correlated with men's long-term risk of developing clinically significant prostate cancer, according to a secondary analysis of long-term follow-up results from the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.Once broadly accepted as a tool for the early detection of prostate cancer, PSA screening has become controversial in recent years due to issues of overdiagnosis and overtreatment of slow-growi...

Progress in Metastatic Castration-Sensitive Prostate Cancer: Andrew J. Armstrong, MD, MSc

Last week, Andrew J. Armstrong, MD, MSc, lead researcher of the phase 3 ARCHES trial, spoke with i3 Health about the recent approval of enzalutamide (Xtandi®, Astellas Pharma Inc.) for the treatment of metastatic castration-sensitive prostate cancer (mCSPC) and the variety of options that are now available for the treatment of metastatic hormone-sensitive disease. In this second installment, Dr. Armstrong discusses the ongoing evolution of therapeutic strategies in mCSPC and shares his advice fo...

Insurance Status Contributes to Racial Disparities in Breast Cancer

A new study reports that a lack of adequate health insurance is responsible for nearly half of racial and ethnic disparities in breast cancer stage at diagnosis.Earlier detection and treatment of breast cancer can significantly improve outcomes for patients diagnosed with this disease. However, studies have shown that a higher proportion of women of racial and ethnic minorities present with breast cancer at more advanced stages, negatively impacting their treatment and prognosis. In a study now ...

Enfortumab Vedotin for Advanced Urothelial Carcinoma With Peter H. O'Donnell, MD

The FDA recently approved enfortumab vedotin (Padcev®, Astellas Pharma US, Inc.) for the treatment of patients with locally advanced or metastatic urothelial carcinoma whose disease progressed after treatment with platinum-based chemotherapy and anti–programmed cell death protein 1 (anti–PD-1) or anti–programmed death ligand 1 (anti–PD-L1) therapy. The approval was based on EV-201, a phase 2 trial in which enfortumab vedotin produced a high rate of response in patients with locally advanced or m...

Avapritinib Approved: Gastrointestinal Stromal Tumor With PDGFRA Exon 18 Mutation

​The FDA has approved avapritinib (AyvakitTM, Blueprint Medicines) for adults with unresectable or metastatic gastrointestinal stromal tumor (GIST) with platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutations, including D842V mutations, the most common type of exon 18 mutation. Up to 10% of patients with GIST harbor PDGFRA mutations, which have been linked to GIST development."GIST harboring a PDGFRA exon 18 mutation do not respond to standard therapies for GIST," commented Rich...

Copyright © 2020 i3 Health. All rights reserved.